Start: April 2015
End: April 15, 2022
Blood pressure medications known as angiotensin-receptor blockers have been associated with reduced risk of Alzheimer's because they act on the renin-angiotensin system, a key regulator of blood pressure in the body and brain. These medications appear to slow the progression of Alzheimer's by affecting brain blood flow and plaque levels among Caucasians, but these benefits have not been tested in African Americans. This Phase 1 study will explore if the high blood pressure drug telmisartan (Micardis) affects cognition and biomarkers of Alzheimer's disease in African Americans. Participants will be randomly assigned to take 20 mg telmisartan, 40 mg telmisartan, or a placebo once a day for eight months. Researchers will assess whether telmisartan influences the renin-angiotensin system in the brain and produces favorable effects on brain blood flow and enzymes that cause brain plaques in Alzheimer's disease. Participants will undergo cognitive and blood tests, a brain scan, and lumbar puncture.
Minimum Age: 30 Years
Maximum Age: N/A
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Lead: Emory University
Source: ClinicalTrials.gov ID: NCT02471833